Please assess the completion status of the following clinical trial:

Trial Title: Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Willing to follow all the requirements of the study and available for follow-up for the duration of the study~* Have understanding of the study and provide written informed consent~* Willing to undergo HIV testing and counseling and willing to receive HIV test results~* Willing to use acceptable forms of contraception~Exclusion Criteria:~* HIV infected~* Hepatitis B virus infected~* Hepatitis C virus infected~* Active or untreated syphilis~* Participated in high-risk behavior for HIV infection within 6 months prior to study entry. More information on this criterion can be found in the protocol.~* Any clinically significant abnormality in history or upon examination (e.g., immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive, antiviral, anticancer, or other medications considered significant by the investigator) within 6 months prior to study entry~* Any clinically significant acute or chronic medical condition that, in the opinion of the investigator, would make the volunteer unsuitable for the study~* Live attenuated vaccines within 30 days prior to study entry OR plan to receive a live attenuated vaccine within 60 days after vaccination in this study~* Subunit or killed vaccines within 14 days prior to study entry OR plan to receive a subunit or killed vaccine within 14 days after vaccination in this study~* Blood transfusion or blood products within 120 days prior to study entry~* Immunoglobulin within 60 days prior to study entry~* Participation in another investigational product clinical trial in the 3 months prior to study entry OR expected to participate in another investigational trial during this study~* Any other investigational HIV vaccine at any time~* History of severe local or systemic reactogenicity to vaccines or history of severe allergic reactions~* Major psychiatric illness, including any history of schizophrenia or severe psychosis, bipolar disorder requiring therapy, or suicide attempt or suicidal thoughts within the 3 years prior to study entry~* Uncontrolled hypertension~* Pregnant, breastfeeding, or plan to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).